TAP Biosystems has announced that it will be presenting two new bioprocess development webinars on Thursday, October 9th, 2014. The first is at 9am BST / 10am CEST / 1.30pm IST / 5pm KST and the second webinar is at 8am PDT / 11 am EDT / 4pm BST / 5pm CEST.
The live events will detail how to use the ambr250™ high-throughput automated mini bioreactor system for optimizing reproducible feeding regimes to accelerate scale-up bioprocess development of protein-based therapeutics.
During the hour long webinars, bioprocessing expert, Mwai Ngibuini, ambr250 Product Manager at TAP Biosystems, will discuss some of the challenges equipment manufacturers face when trying to model feeding regimes in small scale bioreactors. He will detail current methods used to overcome these issues and explain how the features of the ambr250 mini bioreactor are being utilized to precisely control feed additions.
He will also present technical data from industrial pharmaceutical researchers using ambr250 in their bioprocessing development of mammalian cell lines to produce antibody therapeutics. This data compares the system’s performance to benchtop and pilot scale bioreactors, thus validating how using reproducible feed regimes in a mini bioreactor can improve scalability in upstream process development.
To access the free webinars on October 9th, scientists can register at this link: http://www.tapbiosystems.com/ambr250_webinar/ambr250PrecisionfeedOct14.htm
Mwai Ngibuini, ambr250 Product Manager at TAP Biosystems commented: “Mini bioreactors offer a strategy for rapidly assessing a large number of process parameters and reducing bioprocess development time. However, many don’t allow consistent feeding regimes, which can lead to run-to-run variability and becomes a challenge when trying to use that data to scale-up the process.”
Ngibuini added: “I am delighted to be hosting these webinars to present industrial, proof-of-concept data which demonstrate consistent feeding strategies using ambr250. I look forward to discussing with scientists attending the webinars how they could apply the ambr250 as a true scale-down model in their workflow and the ways in which this could help reduce manufacturing costs and accelerate development of their protein-based therapeutics.”